

Intercept Presentations	First Author	Abstract Link
Cholestasis		
Long-Term Efficacy and Safety of Obeticholic Acid in Patients With PBC From the POISE Trial Grouped Biochemically by Risk of Disease Progression	Bowlus	https://doi.org/10.1002/hep.31579 Poster #1250
Long-Term Efficacy and Safety of Obeticholic Acid in Primary Biliary Cholangitis: Responder Analysis of Over 5 Years of Treatment in the POISE Trial	Hansen	https://doi.org/10.1002/hep.31579 Poster #1251
Real-World Effectiveness of Obeticholic Acid in Patients With Primary Biliary Cholangitis	Gish	https://doi.org/10.1002/hep.31579 Poster #1268
Primary Biliary Cholangitis: Patient Characteristics and the Healthcare Economic Burden in the United States	Gish	https://doi.org/10.1002/hep.31579 Poster #1259
NASH		
Noninvasive Assessments to Identify Patients With Advanced Fibrosis Due to NASH: Screened Population From the REGENERATE Trial	Boursier	https://doi.org/10.1002/hep.31578 Oral #56
Evaluation of Obeticholic Acid Efficacy in Patients With NASH Who Were Monitored Using Noninvasive Tests: A Post Hoc Analysis of the REGENERATE Trial	Alkhoury	https://doi.org/10.1002/hep.31578 Oral #70
Identification of Patients with Nonalcoholic Steatohepatitis (NASH) in an Electronic Health Record (EHR) Database	Bertoia	https://doi.org/10.1002/hep.31579 Poster #1599
FIB-4 and FibroScan Can Identify Patients With Nonalcoholic Fatty Liver Disease Who Are at Risk of Liver-Related Events: Results of a Longitudinal Analysis With Comparison with Liver Biopsy	Boursier	https://doi.org/10.1002/hep.31579 Poster #1589
Identification of Undiagnosed NASH: Development and Application of a Real-World Prediction Model	Kponee-Shovein	https://doi.org/10.1002/hep.31579 Poster #1520
A Fecal Microbiome Signature for NASH Based on Analysis of a REGENERATE Sub-Study Compared With Three Healthy Control Populations	Wu	https://doi.org/10.1002/hep.31579 Poster #1510
Predicted Long-Term Clinical Outcomes of Obeticholic Acid (OCA) for the Treatment of Patients with Advanced Fibrosis Without Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Compared to Standard of Care in the USA	Barritt	https://doi.org/10.1002/hep.31579 Poster #1542
Characteristics and Care Patterns of Real-World Nonalcoholic Steatohepatitis (NASH) Patients With and Without Liver Biopsy	Esposito	https://doi.org/10.1002/hep.31579 Poster #1576
Economic Burden of NASH-Associated Cirrhosis: US Payer's Perspective	Mozaffari	https://doi.org/10.1002/hep.31579 Poster #1584

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
Cholestasis		
Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the POISE criteria	Hirschfield	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI146
Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 Months in patients with primary biliary cholangitis	Jones	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract THU114
Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study	Leroy	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI180
NASH		
Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the REGENERATE study	Younossi	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI080
Obeticholic acid (OCA) improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study	Boursier	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract AS075
Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the REGENERATE trial	Loomba	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI066
The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care	Pais	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract THU048
Noninvasive tests for assessing fibrosis in patients with non-alcoholic fatty liver disease: an evaluation of combining test results	Vick	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI009
Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study	Loomba	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract LBP19

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Durability of Biochemical Improvements Through Six Years of Open-Label Treatment With Obeticholic Acid in Patients with PBC who Did Not Achieve the POISE Criteria	Hirschfield	https://doi.org/10.1016/S0016-5085(20)33875-0 Abstract 687
Predicted Risk of End-Stage Liver Disease Utilising the UK-PBC Risk Score With Continued Standard of Care and Subsequent Addition of Obeticholic Acid for 60 Months in Patients With Primary Biliary Cholangitis	Jones	https://doi.org/10.1016/S0016-5085(20)34100-7 Abstract Su1647
<i>NASH</i>		
Obeticholic acid (OCA) improves experimental noninvasive markers of NASH and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study	Boursier	https://doi.org/10.1016/S0016-5085(20)33836-1 Abstract 334
Obeticholic Acid Improves Hepatic Fibroinflammation as Assessed by Multiparametric Magnetic Resonance Imaging: Interim Results of the REGENERATE Trial	Lomba	https://doi.org/10.1016/S0016-5085(20)34278-5 Abstract Tu1665
Obeticholic Acid Improves Transaminases in Patients With Non-alcoholic Steatohepatitis: Results From the 18-Month Interim Analysis of the REGENERATE Study	Rinella	https://doi.org/10.1016/S0016-5085(20)34184-6 Abstract Mo1448
Obesity-specific Health-related Quality of Life In Patients With Non-alcoholic Steatohepatitis: Results From the REGENERATE Study	Younossi	https://doi.org/10.1016/S0016-5085(20)33828-2 Abstract 326

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Effects of Obeticholic Acid on APRI and GLOBE Score in Patients with Primary Biliary Cholangitis	Harms	https://doi.org/10.1002/hep.30941 Abstract 1261
Durable Response in the Markers of Cholestasis Through 5 Years of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis	Nevens	https://doi.org/10.1002/hep.31033 Late Breaking Abstract 06
<i>NASH</i>		
Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): A secondary analysis of the phase 3 REGENERATE study	Anstee	https://doi.org/10.1002/hep.30941 Abstract 1715
Obeticholic Acid Treatment in Patients with Non-Alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages	Sanyal	https://doi.org/10.1002/hep.30940 Abstract 34
The impact of pruritus on patient-reported outcomes in patients with non-alcoholic steatohepatitis treated with obeticholic acid	Younossi	https://doi.org/10.1002/hep.30940 Abstract 56
Assessment of patient-reported outcomes in patients with NASH treated with obeticholic acid: Results from REGENERATE phase 3 clinical trial	Younossi	https://doi.org/10.1002/hep.30941 Abstract 2324
Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Patients with Nonalcoholic Steatohepatitis and Fibrosis or Cirrhosis	Alkhoury	https://doi.org/10.1002/hep.30941 Abstract 2294
The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries	Newsome	https://doi.org/10.1002/hep.30941 Abstract 395
Long-Term Outcomes of Patients with Advanced Fibrosis due to Non-Alcoholic Steatohepatitis (NASH) at Risk of Progressing to Cirrhosis Under Standard of Care	Pais	https://doi.org/10.1002/hep.30941 Abstract 1217

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Long-Term Obeticholic Acid Treatment is Associated with Improvements in Collagen Morphometry in Patients with Primary Biliary Cholangitis	Kremer	https://doi.org/10.1016/S0168-8278(19)30204-1 Abstract 033
Long Term Assessment of the Effects of Obeticholic Acid in Patients with Primary Biliary Cholangitis on Immune and Inflammatory Markers	Hirschfield	https://doi.org/10.1016/S0168-8278(19)30204-1 Abstract 026
<i>NASH</i>		
Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH	Younossi	https://doi.org/10.1016/S0618-8278(19)30006-4 Abstract 06
Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH (Study 117: HepQuant Disease Severity Index in NASH)	Alkhoury	https://doi.org/10.1016/S0168-8278(19)30203-X Abstract 18

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
From Guidelines to Uniform Pan-healthcare Professional Practice: Development of an International Consensus Care Pathway for the Diagnosis and Management of Primary Biliary Cholangitis	Hirschfield	http://dx.doi.org/10.1002/hep.30257 Abstract 1886
Hepatic Safety Overview of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis	Pockros	http://dx.doi.org/10.1002/hep.30257 Abstract 1931
<i>NASH</i>		
Obeticholic Acid Was Safe and Well Tolerated in Patients with NASH and Compensated Cirrhosis: A Secondary Analysis of the CONTROL Study	Halegoua-De Marzio	http://dx.doi.org/10.1002/hep.30256 Abstract 71
CONTROL: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Patients with Nonalcoholic Steatohepatitis	Pockros	https://doi.org/10.1002/hep.30257 Abstract 1672
Efficacy and Safety of Obeticholic Acid in Patient with Nonalcoholic Steatohepatitis and Significant Fibrosis Using Endpoint Definitions and Populations Accepted for Registrational Studies	Neuschwander-Tetri	http://dx.doi.org/10.1002/hep.30257 Abstract 1673
Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Alkhoury	http://dx.doi.org/10.1002/hep.30257 Abstract 1709

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

EASL 2018 Intercept Presentations

Title	First Author	Abstract Link
Research		
Steroidal and non-steroidal FXR agonists elicit clinically-relevant lipoprotein profiles in mice with chimeric humanized livers	R. Papazyan	https://doi.org/10.1016/S0168-8278(18)30340-4
Cholestasis		
Long-Term Obeticholic Acid (OCA) Treatment Associated with Reversal or Stabilization of Fibrosis/Cirrhosis in Patients with Primary Biliary Cholangitis (PBC)	C.L. Bowlus	https://doi.org/10.1016/S0168-8278(18)30441-0
Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202	G.M. Hirschfield	https://doi.org/10.1016/S0168-8278(18)30680-9
Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis	M. Trauner	https://doi.org/10.1016/S0168-8278(18)30665-2
Independent Predictors of Primary Biliary Cholangitis (PBC) At High Risk for Progressive Course in the United States: Data from a Large-Real World Database	Z. Younossi	https://doi.org/10.1016/S0168-8278(18)30686-X
Primary Biliary Cholangitis in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC	C. Bowlus	https://doi.org/10.1016/S0168-8278(18)30673-1
Obeticholic acid response in primary biliary cholangitis associated with differential expression of antigen presentation, Wnt signalling and mRNA splicing	M. Seifi	https://doi.org/10.1016/S0168-8278(18)31133-4
Biliary Atresia		
Disease severity, obeticholic acid disposition and dose selection in patients with biliary atresia	J.E. Edwards	https://doi.org/10.1016/S0168-8278(18)31518-6
NASH		
Combined Administration of Obeticholic Acid (OCA) and GFT-505: Additive Histological Improvements in Mice with Diet-induced and Biopsy-confirmed Non-alcoholic Steatohepatitis (NASH)	J. Roth	https://doi.org/10.1016/S0168-8278(18)30913-9
Fibrosis involves increased fibroblast and hepatocyte collagen species, reflecting the interstitial and basement membrane matrix: Restoration of the local tissue milieu with FXR agonism	J. Roth	https://doi.org/10.1016/S0168-8278(18)31034-1
Treatment with obeticholic acid does not show liver enzyme elevations consistent with liver toxicity based upon evaluation of Drug-Induced Severe Hepatotoxicity (eDISH)	A. Sanyal	https://doi.org/10.1016/S0168-8278(18)31420-X

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested